Genmab — Januar 2024

[E_L]

But now that we have you here Monforte, everything still going well for you?

[E_L]

JPM24: Johnson & Johnson CEO says Tecvayli, Talvey and several other meds are set to trounce analyst estimates https://www.fiercepharma.com/pharma/jpm24-johnson-johnson-ceo-says-tecvayli-talvey-and-several-other-meds-can-vastly-outperform

[Solsen]

Hvis Carvykti slettes af listen i MM pga utilsigtede bivirkninger står Genmab godt og det kan være det JNJ forbereder investorerne på.Hvis JNJ taber voldgiften eller er interesseret i hexa-38 er der kun et alternativ for dem

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[bibob]

God morgen.

[Darvin]

Cramer flytter fokus til Health Car

[Darvin]

According to Cramer, health-care companies can yield bigger percentage gains than tech companies, for which investors should be looking. He also pointed out the large number of multibillion-dollar biopharma acquisitions announced at the end of 2023, saying investors should be on the lookout for more industry mergers.
9/1 2024 07:03 af Darvin
“Don’t forget that what we care about is percentage gains, not incremental gains,” he said. “And I think we can find bigger percentage gains in health care

[Darvin]

“Don’t forget that what we care about is percentage gains, not incremental gains,” he said. “And I think we can find bigger percentage gains in health care,

[ProinvestorNEWS]

Tirsdagens danske avisuddrag med Vestas, Pandora og Genmab https://www.proinvestor.com/investornyt/1100847/tirsdagens-danske-avisuddrag-med-vestas-pandora-og-genmab

[ProinvestorNEWS]

Kursmålet for Genmab sænkes med 14 pct. af canadisk finanshus https://www.proinvestor.com/investornyt/1100852/kursmalet-for-genmab-saenkes-med-14-pct-af-canadisk-finanshus

[JKY_VH]

Tak PN 7:47, så er der 14% upside ifølge canadiske RBC og god morgen;-)

[Monforte]

#EL, yes, still going strong, planning 10-years anniversary with the DARA-treatment in june without any complications.

[E_L]

that is great to hear! 10 years already...just amazing!

[E_L]

Novartis Strategy
& Growth Update
from
J.P. Morgan Healthcare Conference https://www.novartis.com/sites/novartis_com/files/2024-jpm-novartis-strategy-growth-update.pdf

[E_L]

Novartis indicates Kesimpta Peak sales
(approx.) $4bn

[E_L]

JPM24: As cancer players jump head-first into ADC field, Novartis CEO explains how he's resisted the temptation https://www.fiercepharma.com/pharma/jpm24-cancer-players-jump-head-first-adc-field-novartis-ceo-explains-how-hes-resisted

[ProinvestorNEWS]

TIVDAK (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug https://www.proinvestor.com/investornyt/1100949/tivdak-tisotumab-vedotin-tftv-supplemental-biologics-license-application-accepted-for-priority-review-by-us-food-and-drug

[E_L]

BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference https://investors.biontech.de/news-releases/news-release-details/biontech-outlines-2024-strategic-priorities-42nd-annual-jp

[E_L]

"Based on emerging clinical data, the companies have planned engagement with health authorities on the design of a Phase 3 trial for BNT311/GEN1046 (acasunlimab) in second line NSCLC. The companies intend to share the data on which this decision was based at a medical conference in 2024."